FeesSafety
Pluang+

Polaryx Therapeutics advances PLX-200 trial for rare pediatric diseases with new clinical site activation.

Market News
20 Nov 2026, 15:30 WIB
GlobeNewsWire
View Source
Bullish
Polaryx Therapeutics advances PLX-200 trial for rare pediatric diseases with new clinical site activation.

Polaryx Therapeutics highlighted its participation in key scientific and patient advocacy events as it progresses the SOTERIA Phase 2 trial of its lead drug candidate, PLX-200, targeting four rare pediatric lysosomal storage disorders (LSDs). The company recently activated its first clinical trial site at Boys Town National Research Hospital and presented updates on its development program at the NCL conference. The SOTERIA trial aims to assess safety and efficacy of PLX-200 in children with CLN2, CLN3, Krabbe, and Sandhoff diseases, with plans to initiate trials in the US, Europe, and Asia. This progress underscores Polaryx's commitment to addressing unmet needs in rare pediatric diseases through innovative therapies.

Polaryx Therapeutics' recent participation in scientific and advocacy events provides context for readers. For those following the health sector, 77 of 150 US health stocks on Pluang rose while 66 fell as of Nov 20, 2026 20:02 WIB. Notable movers include TransMedics Group Inc (TMDX) at USD 90.97 with a 3.24% decline and 72% sell order activity, AdaptHealth Corp (AHCO) at USD 7.03 down 3.03%, and Cronos Group Inc (CRON) at USD 2.99 down 2.92%.

More News

Robinhood and Nu compete as top fintech disruptors with strong growth but different risks and valuations.

Robinhood and Nu compete as top fintech disruptors with strong growth but different risks and valuations.

Robinhood Markets and Nu are leading fintech disruptors with distinct strengths: Robinhood expands its retail platform with new asset classes and institutional crypto services, generating $5.1 billion revenue and $2 billion net income in the past yea...

Market News
Bullish
9 minutes ago
Industrial stocks Quanta, Eaton, and Vertiv poised for strong 2027 growth on US electricity infrastructure demand.

Industrial stocks Quanta, Eaton, and Vertiv poised for strong 2027 growth on US electricity infrastructure demand.

Quanta Services, Eaton, and Vertiv are set to benefit from rising US electricity infrastructure investments in 2027. Quanta has a record $63.7 billion backlog supporting future revenue, Eaton sees surging demand for electrical equipment across multip...

Bullish
19 minutes ago
Robotaxis expected to scale globally by 2030, with major growth opportunities for Uber, Tesla, Rivian, and Lucid.

Robotaxis expected to scale globally by 2030, with major growth opportunities for Uber, Tesla, Rivian, and Lucid.

Robotaxis are predicted to become widely available by 2030, with experts expecting large-scale adoption in major cities across the U.S. and China. This new market could reach up to $10 trillion globally in the long term, according to some forecasts. ...

Bullish
34 minutes ago
Anthropic's $900B compute deals highlight SpaceX's flexible contract and potential revenue boost.

Anthropic's $900B compute deals highlight SpaceX's flexible contract and potential revenue boost.

Anthropic has committed nearly $901 billion to infrastructure deals with major tech companies including SpaceX, Microsoft, Alphabet, and Amazon, spreading spending through 2045. Notably, Anthropic's contract with SpaceX allows cancellation with 90 da...

Market News
Neutral
44 minutes ago
Bloom Energy's revenue soars 138% but free cash flow stays negative amid high costs.

Bloom Energy's revenue soars 138% but free cash flow stays negative amid high costs.

Bloom Energy reported a 138% year-over-year revenue increase in Q3 and raised its full-year revenue guidance, yet its free cash flow remained negative at about $181 million due to high operating cash burn and capital expenditures. Despite a 50% stock...

Market News
Neutral
49 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App